Abstract
Synthetic cathinones are designer drugs of the phenethylamine class, structurally and pharmacologically similar to amphetamine, 3,4-methylenedioxymethamphetamine (MDMA), cathinone and other related substances. New analogues, legal at least, until formally banned (a time consuming process), are introduced almost daily The United Nations estimates nearly 250 new drug analogues are produced per year. Various combinations of these drugs are sold under the name of “bath salts.” They can be ingested by any route and some appear capable of causing great harm, mostly behavioral. One drug in particular, MDVP, appears to frequently cause symptoms indistinguishable from the classic findings in Excited Delirium Syndrome (ExDS). Little is known about the pathology or clinical toxicology of these drugs but their molecular mechanism of action seems to be identical with that of cocaine. This mini-review examines what little is known on the subject and explains the suspected mechanisms of excited delirium syndrome.
Keywords: “Bath salts”, cathinones, methedrone, methelone, MDMA, MDVP.
Graphical Abstract
Current Neuropharmacology
Title:Cathinone Neurotoxicity (“The “3Ms”)
Volume: 13 Issue: 1
Author(s): Steven B. Karch
Affiliation:
Keywords: “Bath salts”, cathinones, methedrone, methelone, MDMA, MDVP.
Abstract: Synthetic cathinones are designer drugs of the phenethylamine class, structurally and pharmacologically similar to amphetamine, 3,4-methylenedioxymethamphetamine (MDMA), cathinone and other related substances. New analogues, legal at least, until formally banned (a time consuming process), are introduced almost daily The United Nations estimates nearly 250 new drug analogues are produced per year. Various combinations of these drugs are sold under the name of “bath salts.” They can be ingested by any route and some appear capable of causing great harm, mostly behavioral. One drug in particular, MDVP, appears to frequently cause symptoms indistinguishable from the classic findings in Excited Delirium Syndrome (ExDS). Little is known about the pathology or clinical toxicology of these drugs but their molecular mechanism of action seems to be identical with that of cocaine. This mini-review examines what little is known on the subject and explains the suspected mechanisms of excited delirium syndrome.
Export Options
About this article
Cite this article as:
Karch B. Steven, Cathinone Neurotoxicity (“The “3Ms”), Current Neuropharmacology 2015; 13 (1) . https://dx.doi.org/10.2174/1570159X13666141210225009
DOI https://dx.doi.org/10.2174/1570159X13666141210225009 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Recent Developments in Nanoparticle Based Targeted Delivery of Chemotherapeutics
Current Bioactive Compounds Congenital Disorders of Glycosylation (CDG): Update and Perspectives
Current Pediatric Reviews Application and Future Prospect of Extracellular Matrix Targeted Nanomaterials in Tumor Theranostics
Current Drug Targets Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Assessing Cardiovascular Risk in Patients with Diabetes: An Update
Current Cardiology Reviews Complex Inheritance for Susceptibility to Sudden Cardiac Death
Current Pharmaceutical Design The Mechanism of Carvedilol in Experimental Viral Myocarditis
Current Pharmaceutical Design Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety EDITORIAL [Hot Topic: Diabetes Cardiovascular Complications (Guest Editor: Costanza Emanueli)]
Endocrine, Metabolic & Immune Disorders - Drug Targets Antivitamin K Drugs in Stroke Prevention
Current Vascular Pharmacology The Significance of Renal Function in Response to Cardiac Resynchronisation Therapy – A Piece of a Much Larger Puzzle
Current Vascular Pharmacology Cardiovascular Surveillance of Duchenne and Becker Muscular Dystrophy and Female Carriers
Current Pediatric Reviews Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels
Current Neuropharmacology Acute Myocarditis in Children: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Cardiac Effects of Anabolic Steroids: Hypertrophy, Ischemia and Electrical Remodelling as Potential Triggers of Sudden Death
Mini-Reviews in Medicinal Chemistry Use of BNP and CRP as Biomarkers in Assessing Cardiovascular Disease:Diagnosis Versus Risk
Current Vascular Pharmacology Revised Genetic Classification of Limb Girdle Muscular Dystrophies
Current Molecular Medicine Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Oxidative Stress and Endothelial Dysfunction in Cardiovascular Disease: Mitochondria-Targeted Therapeutics
Current Medicinal Chemistry Selective Inhibition of Phosphodiesterases 4A, B, C and D Isoforms in Chronic Respiratory Diseases: Current and Future Evidences
Current Pharmaceutical Design